Globe Newswire
ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $17.8 million in 1Q 2024; total operating expenses decreased 25% (adjusted total operating expenses decreased 16%)1 compared to 1Q 2023
Successfully completed LOTIS-7 dose escalation and initiated expansion in 2L+ DLBCL
Initial MZL IIT Phase 2 data from 15 patients showed 13 patients with CR and 1 patient with PR; encouraging data compared to current treatments in area with high unmet medical need
Research... (continue reading...)
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation of Clofazimine Inhalation Suspension (MNKD-101) for the treatment of nontuberculous... (continue reading...)
VANCOUVER, British Columbia, May 06, 2024 (GLOBE NEWSWIRE) -- Pulsar Helium Inc. (TSXV:PLSR & OTCQB: PSRHF) (“Pulsar” or the “Company”) is pleased to announce that the Minnesota Department of Transport has announced that Spring road restrictions in the north frost zone have ended (12:01 AM Monday, May 6). The Company will immediately recommence field operations at the Jetstream #1 appraisal well* at its flagship Topaz helium project.
Activities will initially... (continue reading...)
VANCOUVER, British Columbia, May 06, 2024 (GLOBE NEWSWIRE) -- Today marks a pivotal development for Brains Bioceutical Corp ("Brains Bio"), as it significantly strengthens its Veterinary Health Division. This enhancement is led by John Boshart, a distinguished figure in animal health with profound experience from his tenures at Pfizer Animal Health and Zoetis. His arrival signifies a strategic consolidation of talent and expertise aimed at redefining standards within... (continue reading...)
PRINCETON, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2024.
First Quarter 2024 Highlights
- First quarter revenues of $368.9 million declined 3.1% on a reported basis and declined 2.5% on an organic basis compared to the prior year. Revenue increased 1.6% on an organic basis excluding Boston
- First... (continue reading...)
More Globe Newswire
View Older Stories-
AsclepiX Therapeutics Completes Enrollment in DISCOVER Trial for Neovascular Age-Related Macular Degeneration (nAMD)
-
USI Insurance Services Acquires Hignojos Insurance Agency
-
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma
-
AI and Big Data Take the Centre Stage in Central Asia at Beetech 2024 Hosted by Beeline Kazakhstan and QazCode
-
Ferrari N.V.: Periodic Report on the Buyback Program
-
Prepayments, Realkredit Danmark A/S
-
Crypto Rating Agency ARIA Creating a New Investment Risk Metric with Platform Launch
-
The News Forum - Energy Creates Launches Nation-Wide Scholarship Contest Offering $500,000 in Prizes to Youth 15 – 25
-
Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia
-
Orion Corporation: Managers’ transactions – Veli-Matti Mattila
-
Orion Corporation: Managers’ transactions – Maziar Mike Doustdar
-
Orion Corporation: Managers’ transactions – Kari Jussi Aho
-
Orion Corporation: Managers’ transactions – Karen Lykke Sørensen
-
Orion Corporation: Managers’ transactions – Hilpi Rautelin
-
Orion Corporation: Managers’ transactions – Henrik Stenqvist
-
Orion Corporation: Managers’ transactions – Eija Ronkainen
-
Orion Corporation: Managers’ transactions – Ari Lehtoranta
-
Godkendelse af afdelingsfusion og vedtægter i Investeringsforeningen SEBinvest
-
SHARE BUYBACK TRANSACTIONS
-
Virbac : Declaration of the number of shares and voting rights
-
Curium Announces First Commercial Doses in Germany of PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer
-
Correction: Share buy-back programme - week 18
-
Mattermost Playbooks Elevate Real-Time Cybersecurity Automation to Accelerate Compliance with New SEC & CISA Regulations
-
Mattermost Playbooks Elevate Real-Time Cybersecurity Automation to Accelerate Compliance with New SEC & CISA Regulations
-
Master the complexities of Pillar Two with our New Online Course!
-
Danske Bank share buy-back programme: Transactions in week 18
-
Alm. Brand A/S – Weekly report on share buybacks
-
Prepayments (CK93) - Totalkredit A/S
-
Prepayments (CK93) - Nykredit Realkredit A/S
-
Danske Bank A/S, transactions by persons discharging managerial responsibilities
-
Reporting of transactions made by members of the Board of Directors or Executive Management or their Closely Associated Persons
-
Restructuring of ownership in BW Energy Limited and exemption from the mandatory offer obligation
-
Oma Savings Bank Plc: Manager´s Transactions – Closely associated person Tanja Mäkynen
-
Oma Savings Bank Plc: Manager´s Transactions – Jyrki Mäkynen
-
Share buy-back programme - week 18
-
LHV Pank to contest the fine decision by Estonian Financial Intelligence Unit
-
Renault Group: Communication related to the availability of the EMTN base prospectus 2024
-
Transactions in connection with share buyback programme
-
Preliminary data on early redemptions (prepayments)
-
Pierre Anjolras appointed Chief Operating Officer of VINCI
-
Marimekko celebrates the 60th anniversary of the Unikko print in Helsinki and Tokyo with public open-air fashion shows
-
QUADIENT: 2024 Financial calendar - Update
-
Exor Press Release - Periodic Report on the Buyback Program
-
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
-
Health Canada Approves Nexstim NBS 6 System for Treatment of MDD
-
Aktsiaselts Infortar interim report for Q1 2024
-
Fingerprints and Infrafon collaborating on new smart badges for the European Medical and IoT market
-
Subsea7 share repurchases
-
BGHL (GBP): NAV(s)
-
BGHL (EUR): NAV(s)